Longaevus Technologies announced the allocation of Elastin Biosciences
Longaevus Technologies is proud to announce the release of Elastin Biosciences, a significant breakthrough in the field of elastin-related health.
Longaevus Technologies proudly announced the spin-off of Elastin Biosciences, marking a significant breakthrough in elastin-related health. After a year in stealth mode, Elastin Biosciences, led by Chief Scientist Alexey Moskalev and CEO Sherif Idriss, has identified three promising drug combinations that inhibit elastin degradation, boosting its deposition and enhancing aortic elasticity in aged mice in-vivo. With this groundbreaking research, Elastin Biosciences has secured $2.5 million in initial funding and is gearing up for a Series A funding round to advance its regenerative medicine mission.
This achievement not only holds promise for addressing elastin-deficiency-related diseases but also paves the way for innovative treatments promoting overall health and longevity. Elastin Biosciences is now positioned to lead advancements in regenerative medicine, shaping the future of treatment solutions and healthy ageing.
Press-release can be found here: